BRIEF—ICER Draft Evidence Report on Novartis' new MS drug

US cost-effectiveness watchdog the Institute for Clinical and Economic Review ( ICER) has released a  Draft Evidence Report assessing the clinical effectiveness and value of Swiss pharma giant Novartis’ (NOVN: VX) Mayzent (siponimod) for the treatment of secondary progressive multiple sclerosis (SPMS).

Yet to be approved for marketing, Mayzent is set to become the first and only drug proven to delay progression for typical patients living with secondary progressive multiple sclerosis, according to Dr John Tsai, head of drug development and chief medical officer, speaking to The Pharma Letter last month.

This draft report will be open to public comment until April 10, 2019.

Based on stakeholder feedback, the ICER may revise key assumptions and findings for its Evidence Report, which will be published on May 2, 2019.

The Evidence Report will be subject to deliberation during a public meeting of the Midwest Comparative Effectiveness Public Advisory Council), one of ICER’s three independent evidence appraisal committees, on May 23, 2019.